The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)
The summary for the The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00): The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students who have demonstrated potential and interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.
|Federal Grant Title:||The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00)|
|Federal Agency Name:||National Institutes of Health|
|Grant Categories:||Education Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-CA-16-005|
|Type of Funding:||Grant|
|CFDA Numbers:||93.394, 93.395, 93.396, 93.398, 93.399|
|CFDA Descriptions:||Cancer Detection and Diagnosis Research; Cancer Treatment Research; Cancer Biology Research; Cancer Research Manpower; Cancer Control|
|Current Application Deadline:||Feb 19, 2016|
|Original Application Deadline:||Feb 19, 2016|
|Posted Date:||Dec 18, 2015|
|Creation Date:||Dec 18, 2015|
|Archive Date:||Mar 21, 2016|
|Total Program Funding:||$1,400,000|
|Maximum Federal Grant Award:||none|
|Minimum Federal Grant Award:||none|
|Expected Number of Awards:||30|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Public and State controlled institutions of higher education
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
- Additional Information on Eligibility
- Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs) ; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
- Link to Full Grant Announcement
- Grant Announcement Contact
- NIH OER Webmaster
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
National Institutes of Health 301-496-3405
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...